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Purpose: Microbeam radiation therapy is an innovative treatment approach in radiation therapy that
uses arrays of a few tens of micrometer wide and a few hundreds of micrometer spaced planar
x-ray beams as treatment fields. In preclinical studies these fields efficiently eradicated tumors
while normal tissue could effectively be spared. However, development and clinical application of
microbeam radiation therapy is impeded by a lack of suitable small scale sources. Until now, only
large synchrotrons provide appropriate beam properties for the production of microbeams.
Methods: In this work, a conventional x-ray tube with a small focal spot and a specially designed
collimator are used to produce microbeams for preclinical research. The applicability of the developed
source is demonstrated in a pilot in vitro experiment. The properties of the produced radiation field
are characterized by radiochromic film dosimetry.
Results: 50 µm wide and 400 µm spaced microbeams were produced in a 20×20 mm2 sized
microbeam field. The peak to valley dose ratio ranged from 15.5 to 30, which is comparable to
values obtained at synchrotrons. A dose rate of up to 300 mGy/s was achieved in the microbeam
peaks. Analysis of DNA double strand repair and cell cycle distribution after in vitro exposures of
pancreatic cancer cells (Panc1) at the x-ray tube and the European Synchrotron leads to similar results.
In particular, a reduced G2 cell cycle arrest is observed in cells in the microbeam peak region.
Conclusions: At its current stage, the source is restricted to in vitro applications. However, moderate
modifications of the setup may soon allow in vivo research in mice and rats. C 2016 Author(s). All
article content, except where otherwise noted, is licensed under a Creative Commons Attribution (CC
BY) license (http://creativecommons.org/licenses/by/4.0/). [http://dx.doi.org/10.1118/1.4966032]
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cellular response
1. INTRODUCTION
In radiotherapy, as in any other cancer treatment, the aim
is to maximize its lethal effect to the tumor tissue while
reducing side effects to surrounding healthy tissue as much as
possible. Conventionally this aim is achieved by geometrically
concentrating lethal dose levels in the tumor and exposing
organs at risk below the tissue tolerance.
In microbeam radiation therapy (MRT), the tumor is
irradiated by arrays of micrometer wide planar beams of
unconventionally high doses of up to a few hundred Grays
that are separated by several hundred micrometer wide low
dose regions.1 These treatment fields selectively destroy tumor
tissue2–4 while leaving penetrated healthy tissue unimpaired.5,6
The remarkable resistance of normal tissue to microbeams has
been demonstrated in various preclinical studies, beginning
with neutron beams in the 1960s (Refs. 7–10) to synchrotron
generated photon beams in the last 25 years.2,5,6,11,12
Various biological mechanisms have been suggested to
facilitate this microbeam effect. Manifold evidence indicates
that blood vessels and their different repair efficiencies
in malignant and healthy tissue are essential to explain
the differential effect of microbeams.2,4,5,13 Apart from that
experiments demonstrate that bystander signals,14,15 changes
in the immune response, DNA repair, and variations in the cell
cycle16 are important for the biological response to MRT.
Currently, the production of microbeams can only be
facilitated at large synchrotron facilities as the European
Synchrotron (ESRF) in Grenoble (France). This strongly
limits preclinical research with microbeams and therefore
delays their clinical application. MRT requires almost parallel
beams at photon energies of around 100 keV to ensure
sharp beam penumbras and extremely high dose rates to
avoid degradation of the beam profiles due to respiratory
or cardiovascular motion.17 There are several attempts to
move toward alternative microbeam sources, such as laser
accelerated protons18 and inverse Compton scattering.19 Also
x-ray tubes have been suggested as a microbeam source.20
Hadsell et al.21 experimentally realized a preclinical setup
with carbon nanotube x-ray tubes and produced 300 µm wide
microbeams with a dose rate of 21.7 mGy/s per nanotube
cathode. At a source to target distance of apparently 25.4 cm,
a PVDR of 17 was measured for four 1.4 mm spaced beams
at 1.27 mm depth in PMMA. Although this is a major
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step forward to compact microbeam sources, dose rates are
still significantly smaller and beam widths larger than those
achieved with a synchrotron.
In this study, we explore the possibility to use a conven-
tional x-ray tube to produce microbeams for preclinical
studies. The applicability of the developed source for preclin-
ical research in MRT is demonstrated in an in vitro experiment
and compared to experiments at the ESRF. The properties of
the produced MRT field are analyzed and discussed.
2. METHODS
2.A. Setup of the microbeam source
Naturally, synchrotrons are better suited for the production
of microbeams than x-ray tubes. The brilliance of synchrotrons
defined as emitted photons per area, time, and solid angle is ten
orders of magnitude higher than for conventional x-ray tubes.
Therefore, the synchrotron produces highly nondivergent
almost perfectly parallel beams. These beams can easily be
collimated by an array of parallel slits resulting in microbeams
with sharp penumbras whose intensity is not affected by their
distance from the radiation source.
With an x-ray tube as radiation source the situation is
completely different. In order to increase the low dose rate,
the distance between source and experiment or potentially a
patient has to be made as small as possible. However, this will
lead to substantial photon absorption and scattering within
the collimator and the photon flux will decrease according
to the inverse square law with increasing distance from
the radiation source. Moreover, the beam width and beam
spacing will increase and geometric penumbra regions appear
when moving away from the collimator. A parallel multislit
collimator as employed for the microbeam experiments at the
ESRF (Ref. 22) cannot be used.
We have addressed these challenges by designing the
following technical setup. First, an x-ray tube (HPX-160-11,
Varian medical systems, Salt Lake City, USA) was mounted
in an x-ray cabinet (RS160 Cabinet, x-strahl, Camberley, UK)
such that the radiation beam is directed toward the ceiling of
the cabinet. This dual focal spot x-ray tube can be operated
with a focal spot size of 0.4 mm at a maximum power of
800 W. The setup with an upward directed beam allows to
place cells within millimeters from the collimator. There the
beam divergence is expected to have a negligible effect on the
beam shape and the dose rate will be highest.
The production of microbeams is accomplished by a
carefully designed multislit collimator (Fig. 1) mounted at
a distance of 70 mm from the radiation source, which is the
minimal reasonably achievable distance in the cabinet. The
collimator consists of 49 slits cut into a 5 mm thick tungsten
plate, which absorbs 99.9% of the primary radiation. The
50 µm wide and 20 mm long slits, separated by a distance
of 400 µm, are not perpendicular to the plate surface but are
tilted to account for the beam divergence. Therefore, the slit
spacings at the beam-facing surface of the collimator of the
plate are by 26.6 µm smaller than at the top, which leads to
an angle difference of around 18.3 arc min between adjacent
beams. Only the beam aperture at the center of the radiation
field does not have to account for this beam divergence.
The production of the collimator was carried out by state
of the art milling and wire cutting (T&G engineering, Byfleet,
UK). The tolerances were less than 1.5 arc min and 2.5 µm
for slit angles and distances, respectively. Slits are extended
by 1.5 mm in an alternating manner where they start with a
0.3 mm diameter hole. These holes were necessary to get the
wire in place and thread it through the plate before cutting.
The collimator and its design are shown in Fig. 1.
Finally, two motorized translational stages (Thorlabs Ltd.,
Ely, UK) are used to position the collimator with micrometer
accuracy relative to the x-ray tube. A horizontal drive
stepping motor moves the collimator perpendicular to the
central microbeam plane and a vertical drive stepping motor
adjusts the distance between source and collimator surface.
A fluorescence screen and a webcam were setup as a simple
detector system to qualitatively monitor the dose rate behind
the collimator. The setup and a typical detector image are
shown in Fig. 2.
2.B. Dosimetry
Dosimetry was performed in a PMMA phantom of 100
×100×50 mm3 size with Gafchromic® EBT3 films (Ashland,
Covington, USA). EBT3 films are sensitive in a dose range
F. 1. The multislit collimator used to shape microbeams with an x-ray tube: photograph, front view and schematic profile. The latter also shows the PMMA
phantom used for dosimetry on top of the collimator. Films were inserted 1, 5, and 10 mm above the upper collimator surface. The total size of the PMMA
phantom was 100×100×50 mm3. For the in vitro exposures cells were placed 5 mm above the collimator surface inside the PMMA phantom.
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F. 2. (A) shows a photograph of the experimental set-up with multislit collimator (1), horizontal and vertical stepping motors (2), fluorescence screen (3), and
webcam (4). A detector screenshot is shown in (B).
between 0.1 and 40 Gy. Peak and valley dose measurements
were separated. Exposure times were chosen such that peak
or valley doses respectively fell into a range between 1
and 10 Gy. Readout of the exposed films was carried out
with microscopy using the methods described previously.23
Calibration of the films was performed in an open field, i.e.,
without collimator, and reference dosimetry by a semiflex
TW31010 and farmer TW30002-1 ionization chamber (PTW,
Darmstadt, Germany). Anode voltage, current, and filtering
were kept constant between calibration and measurement.
Dosimetry followed the TRS398 protocol,24 including detector
calibration, temperature and pressure corrections, and the
application of beam quality factors kQ.
For all experiments presented here the tube was driven at
160 kV and 5 mA using the small focal spot. Beams were
filtered intrinsically by 0.8 mm beryllium and additionally by
1 mm aluminum. The measured halfvalue layer thickness of
0.31 mm copper was used to determine kQ.
2.C. In vitro experiments
As a proof-of principle study, we performed an in vitro
irradiation of pancreatic cancer cells at our microbeam facility
and compared the results with an analogous experiment at
the European Synchrotron. The aim was to show qualitative
agreement and demonstrate the feasibility of microbeam
experiments with a conventional x-ray tube.
Pancreatic cancer cells, Panc1 (ATCC, Teddington, UK)
were cultured in DMEM 1 g/l or 3.7 g/l glucose me-
dium (ThermoFisher Scientific, Waltham, USA) with 10%
FBS, 1% Pen/Strep Amphotericin B (Lonza biologics PLC,
Slough, UK), 1% MEM NEAA, nonessential amino acids
(PAN Biotech GmbH, Aidenbach, Germany), and 1% Gluta
MAX (ThermoFisher Scientific). Cells were kept incu-
bated at 100% humidity, 5% CO2, and 37 ◦C. Cells were
either seeded on poly-L-lysine (Sigma Aldrich, St Louis,
USA) coated coverslips and cultivated in Nunc Rectangular
Dishes (ThermoFisher Scientific) or on T25 cell culture
flasks.
For the synchrotron exposures cells were grown in T25 cell
culture flasks. During the exposure the flasks were mounted
in upright position behind a 5 mm thick PMMA layer. Film
dosimetry showed that the PVDR is 22.0±0.2. The exposure
was chosen such that peak doses are at 80 Gy. Technical details
of MRT exposures at the ESRF can, for example, be found
in Bräuer-Krisch et al.25
In the exposures with the x-ray cabinet Nunc Rectangular
Dishes were placed in the solid water phantom used for
dosimetry such that the total depth in the phantom and
the distance from the upward (i.e., beam-ward) pointing
collimator surface are both 5 mm. Cells were exposed for 345 s
to achieve a peak dose of 80 Gy. The PVDR was (21±2) as
shown in the following chapter. The MRT field size measured
in all experiments 20×20 mm2 with a microbeam width and
spacing of 50 and 400 µm.
In both experiments the medium was changed before, but
not after irradiation. Cells were fixated for 15 min with
4% formaldehyde solution for 1 and 12 h or 1 and 6 h
after radiation exposure. Immunocytochemical staining was
performed against the phosphorylated histone γH2AX. For
that cells were treated 10 min with 0.3% Triton-X (Sigma
Aldrich) in PBS solution, kept for 60 min in blocking solution,
3% BSA (Sigma Aldrich), 0.3% Trion-X in PBS and incubated
overnight with a 1:1000 diluted antibody solution (Phospho-
Histone H2A.X, Alexa Fluor® 488 conjugate from Cell
Signaling, Cambridge, UK). The signal was intensified by
incubating with a 1:200 diluted secondary antibody solution
for 60 min (AntiRabbit IgG, Alexa Fluor® 488 conjugate
from Cell Signaling). Counterstaining of the cell nuclei was
done with Hoechst 33342.
Epifluorescence microscopy was performed on an auto-
mated scanning microscope. For the x-ray cabinet samples
this was done on a Zeiss scanning microscope and for the
synchrotron samples on a Nikon Zi-HCS system. Coverslips
were mounted on microscope slides before imaging. Image
analysis and cell segmentation were done by the open
source software CellProfiler26 and  (MetaSystems,
Altlussheim, Germany).
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F. 3. Relative output measured by the fluorescence screen detector de-
pending on the horizontal and vertical motor position. The highest output
is reached at 5 mm vertical and 6.1 mm horizontal position.
3. RESULTS
3.A. Dosimetry
The fluorescence screen detector was employed to qualita-
tively monitor the dose rate behind the collimator. The dose
rate depends on the horizontal and vertical collimator position.
In Fig. 3 the mean intensity of all 49 beams is displayed as a
function of the collimator location. In order to achieve more
than 95% of the maximum dose rate, the horizontal position
needs to be adjusted with ±100 µm and the vertical position
with ±1.5 mm accuracy. The highest output is achieved within
1 mm accuracy of the 70 mm focal spot to collimator distance
used for the design of the collimator. In all further experiments
the collimator was positioned at the point with maximum dose
rate.
The results of film dosimetry are summarized in Table I.
Peak dose is defined as the mean dose in the central 10 µm
of the peak and valley dose as the mean dose in the central
140 µm of the trough. At 1 mm depth in solid water the average
dose rate in the peak was measured to be (300±20) mGy/s and
a mean valley dose rate of (10.2±0.5) mGy/s which yields a
ratio between peak and valley dose (PVDR) of (30±3). The
PVDR rapidly decreases with depth. Measurements at 10 mm
depth gave a PVDR of just 15.5±1.5. The rapid degradation
of the PVDR with depth is caused by a growing geometric
penumbra of the divergent x-ray beam.
Measured microbeam profiles at 5 mm depth and peak and
valley dose profiles at 1, 5, and 10 mm depth are presented in
Fig. 4. Valley dose rates at all three depths are very similar and
profiles across the field resemble those measured at the ESRF.
For the x-ray tube the valley dose at the high beam number
T I. Peak and valley doses measured by film dosimetry at 1, 5, and
10 mm depth in a solid water phantom (Fig. 1). PVDRs in this domain are
similar to PVDRs expected at the ESRF for a 20×20 mm2 microbeam field.
Depth (mm) 1 5 10
Peak (mGy/s) 300 ± 20 230 ± 10 170 ± 10
Valley (mGy/s) 10.2 ± 0.5 11.2 ± 0.5 10.7 ± 0.5
PVDR 30 ± 3 21 ± 2 15.5 ± 1.5
edge (right edge of the radiation field in Fig. 4) of the field has
dropped to around 68% of the maximum valley dose. Similar
variations are observed for these field sizes for synchrotron
produced microbeams. However, the valley dose rate profile
is not symmetric around the field center. For the peak doses
an increase from small to large peak numbers is observable.
Especially at 1 mm depth the peak dose increases by more
than 40% across the field. In greater depths beam intensities
become more balanced.
At high beam numbers (right edge of the profiles)
beam intensities vary from microbeam to microbeam in
an alternating manner. At 5 mm depth beams with odd
numbers are slightly higher in their intensity than beams
with even numbers. This pattern is also observable on the
fluorescence screen and is probably related to inaccuracies in
the manufacturing process of the collimator since the wire
cutting direction did also change in an alternating manner. A
small offset in the slit inclination could therefore cause such
an intensity pattern.
The PVDR resembles closely the values obtained at the
synchrotron. To further compare the quality of the produced
microbeams, film dosimetry results were used to measure the
beam penumbras. The beam penumbra width is arbitrarily
defined as the spatial range where the dose falls off from 90%
to 10% of the peak dose. In Fig. 5(A), the beam penumbra
width is visualized for the three examined depths across
the microbeam field. At 1 mm depth the beam penumbra
is constantly around 20 µm wide across the field. At 5 and
10 mm depth the beam penumbra width is around 20 µm for
beam 1. With increasing beam number the penumbras become
wider and reach approximately 33 and 48 µm at the other end
of the field at 5 and 10 mm depth, respectively.
The alignment of the collimator with the x-ray tube causes
the variation in the beam penumbra across the microbeam field
as illustrated in Fig. 5(B). Due to the tilted anode the apparent
focal spot size seen at the collimator depends on the slit
position. The focal spot appears under a wider angle for larger
beam numbers. This directly affects the beam divergence. In
contrast to a point source, where all photons passing through a
collimator slit i have the same direction αi, an extended source
will produce photons that pass the slit in an angle interval
around αi, αi ±∆αi. Figure 5(C) shows results of a Monte
Carlo simulation of the x-ray tube source and the multislit
collimator with the above specifications. The beam divergence
∆α is plotted against the photon position directly behind the
multislit collimator. Each point in the graph corresponds to an
individually simulated photon.
3.B. In vitro experiments
Examples of acquired fluorescence microscopy images
for the experiment at the x-ray cabinet and the European
Synchrotron are shown in Figs. 6(A) and 6(B). Cells in the
microbeam path can visually clearly be distinguished from
cells in the valley. The signal intensity of the green labeled
phosphorylated γH2AX histone is much higher. The cell
density in A is around 200 mm−2 and in B around 600 mm−2.
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F. 4. Results of film dosimetry and microscope readout are displayed for the produced 20×20 mm2 microbeam fields. The top row presents profiles at 5 mm
depth. Due to the limited dose range of the EBT3 films, (A) was obtained with 19 s exposure time and (B) with 746 s exposure time. The bottom row compares
peak (C) and valley (D) dose rates at 1, 5, and 10 mm depth (Fig. 1).
A quantitative evaluation of the γH2AX signal intensity
per cell is shown in Figs. 6(C) and 6(D), at two time points
after radiation exposure across one microbeam. With time, the
intensity of the γH2AX signal decreases in both valley and
peak. In the x-ray cabinet experiment, the signal decreases
by 45% and 40% in the peak and in the valley, respectively.
In the beam penumbra region, the signal decrease is lower at
around 30%. Therefore the width of the penumbra, defined
again as range where the signal lies between 10% and
90% of the peak, becomes wider. One hour after radiation
exposure it is 50 µm and 12 h after exposure 90 µm.
These are both significantly larger than the dose beam
penumbra.
For the synchrotron exposure, the signal reduction is even
more pronounced with 60% in the peak. The reduction in the
valley is just 28% and in the beam penumbra regions 22%.
The γH2AX signal in the synchrotron experiment follows the
microbeam profile more closely and the beam peak appears
sharper. However, due to differences in the experimental
condition, such as cell densities, imaging devices, time points,
F. 5. (A) shows the width of the microbeam penumbras depending on the beam number at 1, 5, and 10 mm depth. The explanation for the penumbra variation
across the field at 5 and 10 mm depth can be understood from the tube-collimator alignment shown in (B). The focal spot appears under different angles. The
effect on the beam divergence is demonstrated in (C), where the deviation from the beam axis (assuming a point source) is plotted over the photon position
directly behind the collimator. Each dot in the graph corresponds to a photon trajectory in a Monte Carlo simulation of the source-collimator setup.
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F. 6. (A) and (B) show a detail of a fluorescence image taken 1 h after radiation exposure with the x-ray cabinet and the ESRF, respectively. The green
GFP-γH2AX (emission at 509 nm) and blue Hoechst 33342 (emission at 461 nm) channel are combined for the images. The image measure in both cases is
(W ×H ) 6.49×4.55 mm2 in size. (C) and (D) show a comparison of the γH2AX signal intensity across a single microbeam, 1 and 12 h after radiation exposure
at the x-ray cabinet and 1 and 6 h at the synchrotron. The Hoechst 33342 signal can be used to analyze the distribution of cells in the cell cycle. A histogram
1 h after exposure is shown in (E). Cells clearly cluster in the G1 and G2 phase. The distribution is independent of the position in the field. This is changing,
however, at later time points. (F) shows the relative increase in G2 cells across an individual microbeam. Cells in the valley accumulate stronger in the G2 phase
than cells in the peak. In (C), (D), and (F) the position of the microbeam is indicated by vertical dashed lines.
and plating surfaces, detailed quantitative comparisons cannot
be validated in this first proof-of-principle experiment.
An interesting behavior of the cells in the microbeam field
can be seen in the bottom row of Fig. 6. Hoechst 33342
fluorescently stains DNA and the signal intensity depends
on the amount of DNA in the cell nucleus. Consequently,
cells in G1 phase before DNA replication have a lower signal
intensity than cells in G2 phase after DNA replication. One
hour after radiation exposure the distribution of cells in the cell
cycle has not significantly changed. Across the microbeam
field the relative cell count histogram over the integrated
Hoechst 33342 intensity yields independently of the position
the distribution shown in Fig. 6(E). Clearly the two peaks
of G1 and G2 phase cells can be distinguished. Figure 6(F)
shows the relative increase of cells in the G2 phase across a
microbeam. Cells are accumulating in the G2 phase, due to the
G2 cell cycle arrest. Interestingly this process is much stronger
at lower doses in the valley than at higher doses in the peak.
The observation was made for both experiments, at the
European Synchrotron and with the x-ray cabinet. Again
quantitative conclusions are difficult to draw. The definition
of G1 and G2 phase cells is arbitrary and based on different
imaging systems. Moreover, the cell cycle is also affected by
the cell density, which was different in both experiments.
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4. DISCUSSION
It was demonstrated that microbeams for in vitro exper-
iments can be produced by conventional x-ray tubes at
reasonable dose rates. With the presented setup, dose rates of
up to 300 mGy/s were reached at a beam width of 50 µm and
a beam-to-beam spacing of 400 µm. Beam-to-beam spacing
and beam width correspond to the specifications envisaged for
future clinical trials at the European Synchrotron (ESRF) in
Grenoble.27 Dose rates for MRT at the European Synchrotron
reach between 8 and 16 kGy/s25 and are orders of magnitude
higher than at an x-ray tube. However, the synchrotron beam
at the ESRF has a maximum height of just 520 µm. Therefore
the target has to be scanned through the beam to produce
higher fields, while the x-ray tube produced microbeam field
can be applied statically. For nonmoving targets, such as in
vitro cells, the absorbed radiation dose should not be affected
by the lower dose rate, although dose rate effects might start
to play a role.28
The dose distribution in a 20 × 20 mm2 microbeam
field produced in the x-ray cabinet is very similar to the
dose distribution obtained in preclinical experiments at the
European Synchrotron. The peak to valley dose ratio ranged
between 15.5 and 30 in measurements at the x-ray cabinet,
similar to values measured and simulated at the ESRF.29,30
Close to the collimator beam, penumbras are sharp and
approximately equal to those measured at the ESRF. The 10%
to 90% penumbra definition yields 29 µm penumbra width
in film dosimetry measurements at the ESRF.23 However, x-
ray tube generated microbeams had clearly wider penumbras
when moving away from the collimator. At 10 mm distance
they attained 50 µm.
While x-ray tube generated microbeams are dosimetri-
cally comparable to microbeams produced at the European
Synchrotrons in terms of beam penumbras and PVDRs, the
achieved uniformity across the microbeam field is lower. Peak
doses at the ESRF vary by just around 5% (Ref. 29) in a 20
×20 mm2 field, whereas peak variations around the mean for
the x-ray tube produced microbeams are as high as 25% in
5 mm depth. There are two main reasons for the fluctuations.
The dominating effect is the alignment between tube and
collimator [Fig. 5(B)]. Each microbeam is produced with a
different projected focal spot size and has a different beam
spectrum due to the heel effect. If beams are labeled as in
Fig. 5(B), then the projected focal spot size is small at small
beam numbers, leading to narrower beam penumbras. How-
ever, the heel effect strongly affects beams with small beam
numbers. These beams therefore have a lower photon fluence
and a harder energy spectrum. While this leads to lower peak
doses close to the collimator, the lower beam divergence at low
beam numbers and absorption of low energy photons at large
beam numbers counterbalance the effect at greater distances
and depths. The second reason for peak dose variations is
manufacturing inaccuracies that lead to the alternating high
and low peak dose pattern (Fig. 4). The uniformity of the beam
penumbras could be considerably increased if the collimator
was rotated by 90◦ around the central beam axis. The setup
will be changed accordingly in future versions. However,
variations in the peak dose are expected to have a negligible
effect on tissue and cell survival, since the fraction of surviving
cells in the peak region is extremely low at high peak doses.
In a pilot experiment, it was demonstrated that the developed
setup is suitable to perform in vitro experiments. For similar
experimental settings, pancreatic cancer cells (Panc1) were
irradiated with a 20×20 mm2 microbeam field with 80 Gy peak
dose, 50 µm beam width, 400 µm beam spacing, and a PVDR of
around 22 at the European Synchrotron and with the developed
setup. The phosphorylation of the histone H2AX was measured
and the G2-cell cycle arrest examined after microbeam irra-
diation. Qualitatively experimental results are similar in both
experiments. Especially the G2 cell cycle arrest in the valley
region is remarkable. Since cells of the Panc1 cell line have a
mutated p53 gene, a G1 cell cycle arrest of cells in the micro-
beam peak can be ruled out. However, it should be noted that
these results have to be further validated and more experiments
will be carried out with the developed source to investigate the
in vitro behavior of cells after microbeam treatment.
5. CONCLUSION
Research in microbeam radiation therapy is so far almost
exclusively restricted to large synchrotrons. In this work,
it was shown that conventional x-ray tubes could provide
an alternative radiation source. With a specially designed
multislit collimator, microbeams were produced for in vitro
experiments at a dose rate of up to 300 mGy/s. In a first proof-
of-principle study, the feasibility of the developed source for
the in vitro experiments is demonstrated and first results show
that for both radiation sources the G2 cell cycle arrest is less
pronounced in the peak than in the valley. The authors envisage
a modification of their method and the development of a small
animal microbeam irradiator in the near future. For a clinical
application the limited dose rate is still the main obstacle to
be overcome.
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